Probing the dynamics of prion diseases with amphotericin B.
Amphotericin B (AmB) is one of the rare drugs that affect the course of experimental prion diseases and modify the kinetics of abnormal prion protein accumulation in the central nervous system. Therefore, AmB could be used as a pharmacological tool to contribute to our understanding of the pathogenic mechanisms involved in these neurodegenerative disorders.
Adjou
K T
KT
Service de Neurovirologie, CEA/CRSSA, DSV/DRM, Fontenay aux Roses, France. adjou@dsvidf.cea.fr
Deslys
J P
JP
Demaimay
R
R
Dormont
D
D
D000666:Amphotericin B / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects / Q000473:pathology; D002417:Cattle; D006224:Cricetinae; D004352:Drug Resistance, Microbial; D006801:Humans; D051379:Mice; D015394:Molecular Structure; D011090:Polyenes / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology; D018620:PrPSc Proteins / Q000187:drug effects; D017096:Prion Diseases / Q000209:etiology* / Q000378:metabolism*; D011328:Prions / Q000187:drug effects* / Q000378:metabolism / Q000472:pathogenicity*; D012756:Sheep
D000900:Anti-Bacterial Agents; D011090:Polyenes; D018620:PrPSc Proteins; D011328:Prions; D000666:Amphotericin B